FMC Corp (FMC) Q2 2026 earnings review
Survival Secured, But Operational Bleeding Continues
FMC has officially ended its strategic review, abandoning a potential company sale to focus on a standalone turnaround. The good news: management successfully secured the targeted $1 billion in liquidity through a $400 million equity investment from Tessenderlo Group, the sale of the India business, real estate deals, and a $200 million licensing agreement. The bad news: core operations are still deteriorating. Volume and pricing pressures forced a significant downward revision to full-year guidance, with Adjusted EBITDA now expected to decline 23% at the midpoint.
🐂 Bull Case
Management delivered on its promise to secure ~$1 billion in proceeds to pay down debt, de-risking the balance sheet significantly and removing near-term survival concerns.
While Q3 is guided down 9%, management projects a reversal to 4% growth in Q4, driven by shifting distributor orders, strong Brazilian direct sales, and new active ingredient momentum.
🐻 Bear Case
FY26 Adjusted EBITDA guidance was lowered from a midpoint of $700M to $650M. The core business is still suffering from heavy generic pricing pressure and strained grower margins.
With a company sale off the table, FMC must now organically execute its complex, multi-year manufacturing cost-out strategy to defend its post-patent Rynaxypyr franchise against fierce generic competition.
⚖️ Verdict: 🔴
Bearish. While avoiding a liquidity trap is a major relief, the underlying business is actively decelerating. Lowered guidance and the reliance on a sudden Q4 recovery demand deep skepticism until proven.
Key Themes
Balance Sheet Rescue Plan Achieved
Management successfully hit its ~$1 billion debt paydown target through an aggressive mix of transactions: a $400 million equity investment from Tessenderlo Group, the $252 million India commercial business sale, a $200 million upfront licensing payment for rimisoxafen from Corteva, and a $114 million sale-leaseback of its Delaware property. This decisively stabilizes the balance sheet.
Full-Year Outlook Cut Amidst Volume Declines
Despite achieving balance sheet goals, the core market remains brutal. FY26 revenue guidance (ex-India) was lowered to $3.50B-$3.70B, and Adjusted EBITDA was cut to $620M-$680M. Q2 saw a 10% volume decline (due to lower diamide partner orders and weak North American demand) and a 7% price decline. The turnaround is delayed, and margin compression is accelerating.
The Strategic Review Ends with a Whimper
The Board has formally concluded its exploration of strategic options (announced in Feb 2026), ending speculation of a total company sale. Investors hoping for a quick premium buyout are left relying on FMC's standalone operational plan—a plan currently hampered by mid-to-high single-digit pricing headwinds and restructuring friction.
H2 Seasonality: All Eyes on Q4
Management is forecasting a stark divergence in the second half. Q3 is expected to be weak (-9% revenue, -45% EBITDA YoY) as North American distributors delay purchases. The company assumes these orders are merely deferred, predicting a Q4 reversal to growth (+4% revenue, +5% EBITDA). If this Q3-to-Q4 volume shift fails to materialize, the newly lowered guidance will be missed.
Innovation Portfolio Still Growing
Amidst legacy product weakness, the growth portfolio grew mid-single digits in Q2. Strong performances from new active ingredients and Cyazypyr helped offset declines elsewhere. The $200 million licensing of the rimisoxafen active ingredient to Corteva validates the pipeline's value and injects high-margin cash directly into Free Cash Flow.
Other KPIs
Decelerating aggressively, down 62% from $0.69 in Q2 2025. Driven almost entirely by the drop in operating margins, negative price leverage, and higher interest expenses.
Reversing to positive. A massive $318M improvement vs Q2 2025, but strictly artificially inflated by the $200 million upfront rimisoxafen licensing payment. Underlying operating cash flow generation remains structurally weak amidst the sales downturn.
Guidance
Decelerating. Represents a 7% decline at the midpoint. This is a downgrade from prior expectations, reflecting strained grower margins, lower diamide partner orders, and mid-to-high single digit price compression.
Decelerating. A 23% decline at the midpoint versus 2025. Lowered from the previous $670-$730M range, proving that cost-cutting and favorable FX cannot fully absorb the damage from the volume and price collapse on off-patent products.
Decelerating. A brutal 45% decline at the midpoint versus Q3 2025. Blamed on lower volume as North American distributors shift orders to Q4, compounded by ongoing FX headwinds and price compression.
Reversing. Guided for a 5% increase at the midpoint. This assumes healthy volume growth from direct sales in Brazil and new active ingredients finally offsetting mid-to-high single digit price declines.
Key Questions
Tessenderlo Group Partnership
With Tessenderlo taking a massive $400M equity stake, what strategic synergies or board influences come with this investment, and why did this preempt a full company sale?
Q4 Demand Visibility
Guidance relies heavily on distributors shifting Q3 orders into Q4. In a constrained grower margin environment, what concrete mechanisms or contract commitments ensure these orders won't simply be cancelled?
Rynaxypyr Pricing Floor
Price declined 7% in Q2 due to planned Rynaxypyr actions. Have we hit the pricing floor necessary to defend volume against generic CTPR, or should we expect further aggressive price cuts in 2027?